Mechanism and kinetics study of MG1113, an anti-tissue factor pathway inhibitor antibody promoting hemostasis in...

Targeting tissue factor pathway inhibitor (TFPI) is an emerging hemostatic rebalancing strategy for hemophilia. MG1113 is a humanized monoclonal antibody designed to specifically bind the Kunitz domain (KD)2 of TFPI.

This study elucidated the detailed pharmacologic mechanism of action and the preclinical hemostatic efficacy of MG1113.

In vivo efficacy was evaluated using an acquired hemophilia A (HA) cynomolgus monkey model. In vitro chromogenic assays, factor (F)Xa generation, and clot waveform analysis were performed in human factor-deficient plasmas to assess the dynamics of coagulation. Additionally, a cell-based system using EA.hy926 endothelial cells was established to examine the dual neutralization of TFPI isoforms.

In acquired HA monkeys, a single dose of MG1113 (3 mg/kg) reduced free TFPI levels by 98.8%, shortened the modified prothrombin time and restored thrombin peak height to ∼78% of normal levels. Mechanistically, MG1113 successfully prevented TFPI-mediated inhibition of the extrinsic tenase complex-specifically in the presence of FXa-despite targeting only KD2. MG1113 restored the FXa amplification loop and simultaneously neutralized both plasma-derived TFPI-α and cell-surface TFPI-β. However, despite sufficiently restoring FXa generation, clot waveform analysis revealed that MG1113 exhibited a broader, less intense, and more prolonged coagulation profile compared with the rapid burst characteristic of factor replacement therapy.

MG1113 effectively restores hemostasis by blocking the TFPI/FXa interaction. By systematically lowering the threshold for tissue factor-mediated initiation, MG1113 facilitates physiological restoration of hemostasis. This mechanistic profile-combined with gradual clot kinetics and the advantages of a monoclonal antibody-makes MG1113 suited for routine prophylaxis.